Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2350]

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer

Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer ( Dr Heinz-Josef J. Lenz - Keck School of Medicine of USC, Los Angeles, USA )

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer

Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer ( Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA )

Lung highlights from ESMO 2018

Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy

Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )

Erlotinib for neoadjuvant treatment of EGFR NSCLC

Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical...

Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in...

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...

Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )

Comment on the TRIBE-2 study on first and second-line treatment for metastatic...

Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )

Ceritinib and ribociclib in ALK-positive NSCLC

Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

Ceritinib and ribociclib in ALK-positive NSCLC ( Dr Enriqueta Felip - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Cemiplimab in patients with hepatocellular carcinoma

Dr Michael J. Pishvaian - Georgetown University, Washington, USA

Cemiplimab in patients with hepatocellular carcinoma ( Dr Michael J. Pishvaian - Georgetown University, Washington, USA )

Updates from the EMBRACA trial for advanced breast cancer

Prof Hope Rugo - University of California, San Francisco, USA

Updates from the EMBRACA trial for advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy ( Dr Linda M. Henricks - Netherlands Cancer Institute, Amsterdam, Netherlands )

Key developments in prostate cancer

Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto...

Key developments in prostate cancer ( Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Dr Mark Beresford )

More from ecancer